In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

LivaNova enters loan agreement with BoA Merrill Lynch to support TandemLife acquisition

Executive Summary

In connection with its acquisition of cardiopulmonary device firm TandemLife, LivaNova PLC entered into a $170mm term loan facility with Bank of America Merrill Lynch International Ltd. The facility will terminate on August 14, 2018, but can be extended to February 13, 2019 under certain circumstances. The loan bears interest at a variable annual rate based on LIBOR plus an applicable margin of 0.75% per annum for the first six months, 1% for the following three months, and 1.25% after that time. For TandemLife, LivaNova is paying $200mm up front and up to $50mm in regulatory milestones.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Private Placement

Related Companies